Clinical Data Abivax slides on phase 3 data in ulcerative colitis PharmaphorumShares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.Immunology & InflammationRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer. Immunology & Inflammation Read full story Post navigation Previous: Deep Science Ventures and MDC partner to accelerate brain treatmentsNext: AbiVax falls as safety worries cloud ‘landmark’ immune drug results Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026